The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Inhibition by fluoxetine of cytochrome P450 2D6 activity
Abstract
Potent inhibition of cytochrome P450 2D6 (CYP2D6) in human liver microsomes by fluoxetine and its major metabolite norfluoxetine was confirmed (apparent inhibition constant values, 0.2 mumol/L). Several other serotonergic agents were also found to be competitive inhibitors of this genetically polymorphic enzyme. The O-demethylation ratio of dextromethorphan that expressed CYP2D6 activity in 19 patients receiving fluoxetine fell in the region of the antimode separating the O-demethylation ratio values observed in 208 extensive metabolizers from 15 poor metabolizers of a control group of healthy subjects. Inhibition of CYP2D6 activity in patients undergoing treatment with fluoxetine or other serotonin uptake inhibitors could contribute to toxicity or attenuated response from concurrent medications that are substrates of this enzyme. Other in vitro studies indicated that CYP2D6 catalyzes the O-demethylation of oxycodone to form oxymorphone. This reaction was inhibited by fluoxetine and its normetabolite in liver microsomes from both extensive and poor metabolizer individuals, indicating that these compounds are not selective inhibitors of CYP2D6 activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties
Magnan, J., Paterson, S. J., Tavani, A., & Kosterlitz, H. W. (1982) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/bf00495865 · Cited by 509
Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification
Heim, M., & Meyer, U. A. (1990) · The Lancet · doi:10.1016/0140-6736(90)92086-w · Cited by 447
The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspects
Eichelbaum, M., & Gross, A. S. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90025-w · Cited by 368
Advances in pain research and therapy, Vol. 1
Whitty, C. W. M. (1977) · Neuroscience · doi:10.1016/0306-4522(77)90046-x · Cited by 248
Impact of environmental and genetic factors on codeine analgesia
Desmeules, J., Gascon, M.-P., Dayer, P., & Magistris, M. (1991) · European Journal of Clinical Pharmacology · doi:10.1007/bf00280101 · Cited by 238
Haloperidol Disposition Is Dependent on Debrisoquine Hydroxylation Phenotype
LLerena, A., Alm, C., Dahl, M., Ekqvist, B., & Bertilsson, L. (1992) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199204000-00003 · Cited by 156
Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine
Tate, J. L. (1989) · American Journal of Psychiatry · doi:10.1176/ajp.146.3.399b · Cited by 114
The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam
Lemberger, L., Rowe, H., Bosomworth, J., Tenbarge, J. B., & Bergstrom, R. (1988) · Clinical pharmacology and therapy · doi:10.1038/clpt.1988.52 · Cited by 112
Lasher, T., Fleishaker, J. C., Steenwyk, R. C., & Antal, E. J. (1991) · Psychopharmacology · doi:10.1007/bf02246031 · Cited by 96
Pato, M. T., Murphy, D. L., & DeVane, L. (1991) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199106000-00024 · Cited by 87
Cited by
Pharmacokinetics of selective serotonin reuptake inhibitors
Hiemke, C., & Härtter, S. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00048-0 · Cited by 883
Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance: Part I
Zhou, S.-F. (2009) · Clinical Pharmacokinetics · doi:10.2165/11318030-000000000-00000 · Cited by 756
Bertz, R. J., & Granneman, G. R. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732030-00004 · Cited by 755
Update: Clinically Significant Cytochrome P‐450 Drug Interactions
Michalets, E. L. (1998) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1998.tb03830.x · Cited by 597
Newer antidepressants and the cytochrome P450 system
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.311 · Cited by 482
Metadata
- Authors
- Otton, S. V., Wu, D., Joffe, R. T., Cheung, S. W., & Sellers, E. M.
- Venue
- Clinical Pharmacology and Therapeutics
- Publisher
- Wiley
- Published
- 1993-04
- Volume
- 53
- Issue
- 4
- Pages
- 401-409
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2020944051
- Cited by
- 257
- References
- 12
- FWCI
- 22.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition by fluoxetine of cytochrome P450 2D6 activity. https://app.cochat.ai/papers/10.1038/clpt.1993.43
- The paper
- Otton, S. V., Wu, D., Joffe, R. T., Cheung, S. W., & Sellers, E. M. (1993). Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clinical Pharmacology and Therapeutics. https://doi.org/10.1038/clpt.1993.43
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.